← Back to Search

Treatment Access Strategies for Cervical Cancer in Botswana

N/A
Recruiting
Led By Katharine Rendle, PhD,MSW,MPH
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 90 days of randomization
Awards & highlights

Study Summary

This trial will test ways to help people in Botswana get the cervical cancer treatment they need on time.

Who is the study for?
This trial is for biological females aged 18 or older in Botswana who have been diagnosed with invasive cervical cancer confirmed by pathology. Participants must have their pathology results evaluated at the National Health Laboratory in Botswana.Check my eligibility
What is being tested?
The study is examining four strategies to improve the timeliness of cervical cancer treatment adoption: Low-Touch Strategy, Clinic Outreach, Enhanced Outreach, and High-Touch Strategy. The effectiveness of these approaches will be compared using a practical trial design.See study design
What are the potential side effects?
As this trial focuses on strategies to encourage treatment rather than direct medical interventions, specific side effects are not detailed. However, participants may experience varying levels of healthcare engagement based on the strategy applied.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 90 days of randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 90 days of randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adoption
Secondary outcome measures
Fidelity
Reach: First Appointment
Reach: First Stage
+2 more
Other outcome measures
Clinical Outcomes: Survival
Clinical Outcomes: Treatment

Trial Design

4Treatment groups
Experimental Treatment
Group I: Stage 1 Enhanced Outreach + Stage 2 Low-TouchExperimental Treatment2 Interventions
All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).
Group II: Stage 1 Enhanced Outreach + Stage 2 High-TouchExperimental Treatment2 Interventions
All participants receive direct clinic outreach plus enhanced outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation.
Group III: Stage 1 Clinic Outreach + Stage 2 Low TouchExperimental Treatment2 Interventions
All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging (stage 2).
Group IV: Stage 1 Clinic Outreach + Stage 2 High TouchExperimental Treatment2 Interventions
All participants receive direct clinic outreach to communicate readiness of results (stage 1). Participants who do not attend the clinic by 30 days (non-responders) will receive asynchronous text message reminders using framed messaging in combination with synchronous patient navigation (stage 2).

Find a Location

Who is running the clinical trial?

University of BotswanaOTHER
12 Previous Clinical Trials
5,700 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,672 Previous Clinical Trials
40,925,761 Total Patients Enrolled
Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
144,964 Total Patients Enrolled

Media Library

Stage 1 Enhanced Outreach + Stage 2 High-Touch Clinical Trial Eligibility Overview. Trial Name: NCT05952141 — N/A
Cervical Cancer Research Study Groups: Stage 1 Enhanced Outreach + Stage 2 High-Touch, Stage 1 Clinic Outreach + Stage 2 Low Touch, Stage 1 Enhanced Outreach + Stage 2 Low-Touch, Stage 1 Clinic Outreach + Stage 2 High Touch
Cervical Cancer Clinical Trial 2023: Stage 1 Enhanced Outreach + Stage 2 High-Touch Highlights & Side Effects. Trial Name: NCT05952141 — N/A
Stage 1 Enhanced Outreach + Stage 2 High-Touch 2023 Treatment Timeline for Medical Study. Trial Name: NCT05952141 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers presently looking to enroll individuals for this trial?

"As per clinicaltrials.gov, the recruitment for this trial is currently closed. The study first posted on July 1st 2023 and had its last update made on July 11th 2023. Nevertheless, 395 other trials are still open to applicants at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Strategies to Close the Gap From CC Diagnosis to Treatment in Botswana
Katharine Rendle 2023. "Strategies to Close the Gap From CC Diagnosis to Treatment in Botswana". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05952141.
~453 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top